Givlaari vs Onpattro: Side-by-Side Comparison
Quick answer: Givlaari and Onpattro are both small interfering rna (sirna) therapeutic used for similar indications. They share a mechanism of action but differ in dosing, half-life, side-effect profile, and clinical preferences. Switching between them is a clinical decision.
Side-by-side comparison
| Feature | Givlaari | Onpattro |
|---|---|---|
| Drug class | Small interfering RNA (siRNA) therapeutic | Small interfering RNA (siRNA) therapeutic |
| ATC code | A16AX16 | N07XX |
| Primary indications | Acute hepatic porphyria | Hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy |
| Mechanism | GalNAc-conjugated siRNA that degrades hepatic ALAS1 mRNA, reducing neurotoxic heme intermediates | Lipid nanoparticle-encapsulated siRNA that targets and degrades transthyretin (TTR) mRNA in hepatocytes, reducing serum TTR protein and amyloid deposition |
| Common dose | 2.5 mg/kg SC once monthly | 0.3 mg/kg IV every 3 weeks (max 30 mg) |
| Detail page | Givlaari details → | Onpattro details → |
How to choose between Givlaari and Onpattro
Both medicines belong to the same therapeutic class and address overlapping indications. Selection between them depends on:
- Patient-specific factors: age, kidney and liver function, other medications, allergies, comorbidities
- Specific clinical indication: some class members are preferred for particular conditions or guideline recommendations
- Dosing preference: once-daily vs twice-daily, oral vs injectable, food requirements
- Tolerability: individual side-effect profiles vary even within a class
- Drug interactions: patient's other medications may interact differently with each option
- Cost and availability: generic availability, insurance coverage, regional access
Should you switch?
Switching between class members is a clinical decision, not a self-help one. Reasons your prescriber may consider switching include:
- Inadequate response to current medication
- Side effects affecting quality of life
- New drug interactions due to a recently added medication
- Cost or availability changes
- Updated guidelines favoring a different option
Never switch medications, change dose, or stop without consulting your prescriber.
Related
All Small interfering RNA (siRNA) therapeutic on iMedic · Givlaari full details · Onpattro full details
Frequently asked questions
Is Givlaari better than Onpattro?
Neither is universally 'better.' They are both small interfering rna (sirna) therapeutic with similar mechanisms of action. The right choice depends on the specific clinical situation, patient factors, dosing preferences, drug interactions, and tolerability. Discuss with your prescriber.
Can I switch from Givlaari to Onpattro?
Switching is possible but should be done under clinical supervision. Different class members may not be interchangeable on a 1:1 dose basis, and tapering or transition strategies vary. Never switch on your own.
Do Givlaari and Onpattro have the same side effects?
They share class-wide side-effect tendencies but differ in individual profiles. Some patients tolerate one better than the other. Specific frequency and severity of side effects can be found on each medicine's individual page.
Are Givlaari and Onpattro available as generics?
Generic availability depends on patent status in your country. Most well-established class members are available generically and are clinically equivalent to brand-name versions.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.